<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03007160</url>
  </required_header>
  <id_info>
    <org_study_id>DAWNRAYS101</org_study_id>
    <nct_id>NCT03007160</nct_id>
  </id_info>
  <brief_title>A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence</brief_title>
  <official_title>A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dawnrays Pharmaceutical (Holdings) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dawnrays Pharmaceutical (Holdings) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis
      formation or recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study takes &quot;Rate of stone recurrence&quot; as primary outcome measure, by random, blank
      control, and multicenter clinical trial design method, assess the efficacy and safety of
      potassium citrate extended-release tablets on Urolithiasis formation or recurrence, provide
      evidence for drug re-registration, and observe its efficacy on Urinary calculi such as renal
      tubular acidosis with calcium stone, and uric acid stones with or without calcium stone,
      urinary tract stone of effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Urolithiasis recurrence</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of stone recurrence</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of urine citric acid content compared with baseline</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes of Urine pH value compared with baseline</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2001</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Potassium Citrate Extended-release Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blank control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects do not take the investigational product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Citrate Extended-release Tablets</intervention_name>
    <description>Daily 3.24g, Po ,Tid, each 1.08g/tablets</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Juyuansuanjia Huanshi Pian</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with upper urinary tract calculi surgery and/or ESWL within 3 months；

          -  Stone free or had residual stone fragments with a less than 4 mm diamete；

          -  18-70 years of age; the gender is not limited；

          -  Agree to take effective contraceptive measures during the study period, and female of
             childbearing age whose pregnancy test is negative；

          -  Subjects with no mental illness and language dysfunction, can understand the situation
             of the study and have signed informed consent.

        Exclusion Criteria:

          -  Patients with infectious stones, medical stones and urinary tract obstruction；

          -  Patients with hyperkalemia (K+＞5.5mmol/L) (or patients with factors or disease that
             can cause hyperkalemia), because the further increase in blood potassium can lead to
             cardiac arrest. These factors include disease or strenuous exercise, chronic renal
             failure, uncontrolled diabetes, acute dehydration, excessive, adrenal insufficiency,
             extensive tissue failure. Patients who takes potassium sparing diuretics (such as
             triamterene, spironolactone, amiloride)；

          -  Patients with gastrointestinal disorders, such as peptic ulcer, severe vomiting,
             diarrhea, delayed gastric emptying, intestinal obstruction, etc.；

          -  Combined with cardiovascular, liver, kidney, hematopoietic system, such as severe
             primary disease, or known to affect the survival of serious diseases (such as cancer
             or AIDS), or patients with with disabilities mentally or legally；

          -  Patients with renal insufficiency (1.2 times the upper limit of the normal value of
             serum creatinine and urea nitrogen)；

          -  The recent (within 6 months) with family planners；

          -  Allergic to this product；

          -  To participate in other clinical trials in the past three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhangqun YE, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhangqun YE, M.D.</last_name>
    <phone>(+86)13507191761</phone>
    <email>zhangqun_ye@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dehui LAI</last_name>
      <phone>(+86)13570508863</phone>
      <email>dehuilai@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yongzhong HE</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dehui LAI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changwei LIU</last_name>
      <phone>(+86)13526709425</phone>
      <email>lcw8001@126.com</email>
    </contact>
    <investigator>
      <last_name>Changbao XU</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changwei LIU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolin GUO, M.D.</last_name>
      <phone>(+86)13886042051</phone>
      <email>guoxiaolin0488@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhangqun YE, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaolin GUO, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan No.1 Hospital（Wuhan Integrated TCM &amp; Western Medicine Hospital）</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingxi XU</last_name>
      <phone>(+86)18221683312</phone>
      <email>xuhuaneric@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhong WANG</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mingxi XU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Xiaoshan Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xing WANG</last_name>
      <phone>(+86)18058806706</phone>
      <email>fly115135@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Yi FAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xing WANG</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Sfoungaristos S, Gofrit ON, Yutkin V, Pode D, Duvdevani M. Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options. Expert Opin Pharmacother. 2015 Jun;16(8):1209-18. doi: 10.1517/14656566.2015.1037740. Epub 2015 Apr 16. Review.</citation>
    <PMID>25881654</PMID>
  </reference>
  <reference>
    <citation>Soygür T, Akbay A, Küpeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol. 2002 Apr;16(3):149-52.</citation>
    <PMID>12028622</PMID>
  </reference>
  <reference>
    <citation>Lee YH, Huang WC, Tsai JY, Huang JK. The efficacy of potassium citrate based medical prophylaxis for preventing upper urinary tract calculi: a midterm followup study. J Urol. 1999 May;161(5):1453-7.</citation>
    <PMID>10210371</PMID>
  </reference>
  <reference>
    <citation>Fabris A, Lupo A, Bernich P, Abaterusso C, Marchionna N, Nouvenne A, Gambaro G. Long-term treatment with potassium citrate and renal stones in medullary sponge kidney. Clin J Am Soc Nephrol. 2010 Sep;5(9):1663-8. doi: 10.2215/CJN.00220110. Epub 2010 Jun 24.</citation>
    <PMID>20576821</PMID>
  </reference>
  <reference>
    <citation>Bartoletti R, Cai T, Mondaini N, Melone F, Travaglini F, Carini M, Rizzo M. Epidemiology and risk factors in urolithiasis. Urol Int. 2007;79 Suppl 1:3-7. Review.</citation>
    <PMID>17726345</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

